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Abstract
Background: Wound infection is a common complication in diabetic patients. The progressive spread of
infections and development of drug-resistant strains underline the need for further insights into bacterial behavior
in the host in order to develop new therapeutic strategies. The aim of our study was to develop a large animal
model suitable for monitoring the development and effect of bacterial infections in diabetic wounds.
Methods: Fourteen excisional wounds were created on the dorsum of diabetic and non-diabetic Yorkshire pigs
and sealed with polyurethane chambers. Wounds were either inoculated with 2 × 108 Colony-Forming Units
(CFU) of Staphylococcus aureus or injected with 0.9% sterile saline. Blood glucose was monitored daily, and wound
fluid was collected for bacterial quantification and measurement of glucose concentration. Tissue biopsies for
microbiological and histological analysis were performed at days 4, 8, and 12. Wounds were assessed for
reepithelialization and wound contraction.
Results: Diabetic wounds showed a sustained significant infection (>105 CFU/g tissue) compared to non-diabetic
wounds (p < 0.05) over the whole time course of the experiment. S. aureus-inoculated diabetic wounds showed
tissue infection with up to 8 × 107 CFU/g wound tissue. Non-diabetic wounds showed high bacterial counts at day
4 followed by a decrease and no apparent infection at day 12. Epidermal healing in S. aureus-inoculated diabetic
wounds showed a significant delay compared with non-inoculated diabetic wounds (59% versus 84%; p < 0.05)
and were highly significant compared with healing in non-diabetic wounds (97%; p < 0.001).
Conclusion: Diabetic wounds developed significantly more sustained infection than non-diabetic wounds. S.
aureus inoculation leads to invasive infection and significant wound healing delay and promotes invasive co-
infection with endogenous bacteria. This novel wound healing model provides the opportunity to closely assess
infections during diabetic wound healing and to monitor the effect of therapeutical agents in vivo.
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Background
Wound infection is a major complication in diabetic
patients[1]. According to the American Diabetes Associa-
tion, 25% of people with diabetes will suffer from a
wound problem during their lifetime, and it has been esti-
mated that lower limb amputations in diabetic patients
account for >60% of all amputations performed[2].
Patients with diabetes have impaired wound healing asso-
ciated with multitude of factors, including neuropathy,
vascular disease, and foot deformities[3,4]. At the cellular
level, an increase in the number of acute inflammatory
cells, absence of cellular growth, and migration of the epi-
dermis have been observed[5]. Patients with diabetes
have impaired leukocyte function, and the metabolic
abnormalities of diabetes lead to inadequate migration of
neutrophils and macrophages to the wound, along with
reduced chemotaxis[6,7]. Such cellular changes would
predispose individuals to an increased risk of wound
infection.
Staphylococcus aureus (S. aureus) is the most common sin-
gle isolate (76%) in diabetic wounds and foot ulcers and
leads to alterations in wound healing[8]. Wound infec-
tion can also result in bacteremia or sepsis and is associ-
ated with high morbidity and mortality[9]. In the United
States S. aureus is the most common cause of skin and
soft-tissue infections, as well as of invasive infections
acquired within hospitals[10,11]. Treatment of severe S.
aureus infections is challenging, and the associated mor-
tality rate remains high [12,13]. S. aureus is a gram-posi-
tive bacterium that colonizes the skin and is present in the
anterior nares in about 25–30% of healthy people[14].
Over the last 40 years methicillin-resistant S. aureus
(MRSA) infections have become endemic in hospitals in
the U.S. and worldwide[15]. In 2002, the first clinical iso-
late of vancomycin-resistant S. aureus (VRSA) was identi-
fied in a patient with diabetic foot ulcer[16]. The
progressive reduction of therapeutic efficacies of the avail-
able antibiotics underlines the need for the development
of new therapeutic strategies for the treatment of infected
wounds. However, little is known about the biology of
infections in diabetic wounds, and there are no suitable
animal models. No large animal studies have been per-
formed, since there is no infected diabetic large animal
model available. Small mammals such as rats, rabbits,
and mice are frequently used in wound healing studies
because of cost and ease of handling[17]. Nevertheless
rodents are not optimal for in vivo wound healing studies
because of distinct differences with humans in terms of
anatomy and wound-healing physiology. In contrast, pig
skin resembles human skin anatomically and physiologi-
cally[18], and porcine wound healing has been found to
be significantly similar to that of humans[19,20]. Further-
more, the overall physiology of pigs is close to that of
humans, including the anatomy and function of most key
organ systems. Sullivan et al evaluated 25 different wound
therapies and showed that, in studies that could be com-
pared to human studies, the results in porcine models
agreed with those of human studies 78% of the time,
whereas results of small-mammal models showed only
53% agreement[21]. Thus, the many similarities between
humans and pigs have led to the conclusion that the pig
could provide a suitable model in which to study infected
diabetic wound healing. Moreover, the possibility of cre-
ating multiple experimental wounds in a single animal
reduces the interindividual variability that weakens other
wound infection models. Some porcine models for
wound healing studies have been reported previously,
specifically with non-diabetic burn wounds[22,23] and
excisional wounds[18,24]. We previously developed an
external polyurethane chamber that can be sealed around
the edges of the wound [25,26]. The chamber protects the
wound like a dressing but allows the wound environment
to be standardized and monitored and provides access for
controlled delivery of bacterial strains or potential thera-
peutic agents. It also allows collection and monitoring of
wound fluid for further analysis such as bacterial quanti-
fication, growth factor and cytokine analysis, or gene
expression as well as assessment of wound contraction
and reepithelialization.
The goal of this study was to investigate S. Aureus wound
infections in a diabetic environment in pursuit of an
approach for controlled in vivo monitoring of diabetic
wound infections and effect of therapeutical approaches.
Methods
Animals
All animal procedures were approved by the Harvard
Medical Area Standing Committee on Animals (Protocol
693) and the Harvard Committee on Microbiological
Safety (COMS AR 92-3). All procedures conformed to the
regulations related to animal use and other federal stat-
utes. Four female Yorkshire pigs (2 diabetic, 2 non-dia-
betic; Parson's Farm, MA) weighing 50–60 kg at arrival
were allowed to acclimatize for 1 week prior to initiation
of the experiment. Animals were kept in smooth-walled
stainless steel cages to minimize wound trauma and dis-
ruption of applied wound chambers. During procedures
pigs were kept in a panepinto sling (Universal Metals, Mil-
ford, MA)
Induction of diabetes
Pigs were fasted for 12 hours before diabetes was induced.
On the day of the procedure, the animals received induc-
tion anesthesia with Ketamine (Hospira, Lake Forest, IL)/
Xylazine (Xyla-Ject, Phoenix, St. Josephs, MO) via intra-
muscular injection and were weighed. While animals were
under general anesthesia with isoflurane (2–3 Vol%;
Novaplus, Hospira, IL), a 21-gauge intravenous catheterBMC Surgery 2008, 8:5 http://www.biomedcentral.com/1471-2482/8/5
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(Becton Dickinson, NJ) was inserted into an ear vein.
Streptozotocin (AXXORA, LLC; San Diego, CA 92121
USA) was prepared at a dose of 150 mg/kg body weight
diluted in 9.5 ml/mg sterile saline (0.9% NaCl injection
USP, Baxter) and sterilized by filtration. To keep the blood
glucose concentration between 250 and 500 mg/dl, pigs
received daily injections of 10 IU insulin/10 IU NPH insu-
lin (Humulin, Eli Lilly, IN) subcutaneously. Blood glu-
cose was measured on a daily basis during the experiment.
Wounding and chamber treatment
Fourteen days after induction of diabetes, pigs received
anesthesia as described above. Oxygen saturation and
heart rate were measured with pulse-oximeter ear sensors
(Datex Ohmeda, Columbia, MD); respiratory rate and rec-
tal temperature were also monitored during the proce-
dure. Prior to surgery the porcine dorsum was waxed
(Nair, Church & Dwight, Princeton, NJ) and shaved to
remove hair, and 14 squares measuring 1.5 × 1.5 cm were
outlined using a template and skin marker. The outlines
of the wounds were retraced using a tattoo gun and black
ink (Special Electric Tattoo Marker, Huck Spaulding Enter-
prises, Inc., Voorheesville, NY). The paraspinal area was
washed with alcohol and thoroughly disinfected using
10% povidone iodine paint and then washed with 70%
isopropanol after 20 minutes of incubation. Fourteen full-
thickness excisional wounds (1.5 × 1.5 × 0.5 cm) were cre-
ated using a No. 11 blade. Hemostasis was achieved by
tamponade with sterile gauze. A thin layer of medical
adhesive (No. 7730, Hollister, Libertyville, IL) was
applied to the skin surrounding the wound, and an adhe-
sive polyurethane chamber (Corium International, MI)
was placed over each wound. The edges of the wound
chamber were secured with adhesive Leukotape (BSN
medical Ltd, Brierfield, BB9 5NJ, England) bandage. After
the animal recovered from anesthesia, buprenorphine
(0.005 mg/kg BW) was given intramuscularly every 12
hours for 48 hours. From each chamber, wound fluid was
collected and measured every day and the glucose concen-
tration determined (Ascensia Elite, Bayer Healthcare, NY).
Wound chambers were reinjected daily with 1 ml 0.9%
sterile saline.
Bacterial inoculation
For bacterial inoculation a methicillin-sensitive strain of
S. aureus (American Type Culture Collection no.25923)
was used. A single colony of S. aureus was removed from
the stock, inoculated into Brain Heart Infusion (BHI) cul-
ture media (Becton&Dickinson, Franklin Lakes, NJ USA
07417), and incubated for 18 hours at 37°C. The culture
was centrifuged, the supernatant was discarded, and the
bacterial pellet was resuspended in sterile phosphate buff-
ered saline (PBS) and adjusted to a final concentration of
2 × 108 colony-forming units (CFU)/ml. To immerse the
enclosed wound surface, 1 ml of the bacterial suspension
was injected into each chamber. Control wounds were
injected with 1 ml of sterile PBS (carrier control). After an
inoculation period of 48 hours, solutions were removed
on a daily basis and replaced by 1 ml of sterile 0.9% saline
solution.
Histology
On the final day of the experiment (day 12) pigs were
euthanized (Euthasol; Virbac AH, Fort Worth, TX) and 2
mm cross-sectional wound biopsies were taken from the
remaining wounds. Samples were fixed in 4% buffered
paraformaldehyde and routinely processed for hematoxy-
lin-eosin and tissue gram staining for reepithelialization
and localization of bacteria in the wound tissue.
Assessment of re-epithelialization
Re-epithelialization was calculated by scanning the slides
(Epson Perfection 3600, Epson, CA) and measuring the
epithelial tongues from the computerized image with
Paintshop Pro 7.0 software (Jasc Software, MN) using the
formula (Sum of epithelial tongues)/(Distance between
tattoo marks) × 100.
Wound contraction
Wound contraction was determined by digitized planim-
etry of the tattooed margins. The area of the wounds at
specific days was measured using Scion image software
(Scion, MD), and the percentage of contraction was calcu-
lated by the formula (area at biopsy day)/(area on wound-
ing day) × 100.
Quantification of bacteria
Biopsy specimens (3 mm punch-biopsy) for bacterial
quantification in tissue were obtained on days 4, 8, (n = 3
wounds for S. aureus-inoculated wounds) and day 12 (n =
4 wounds for all groups with 4 punch biopsies per
wound). All biopsied wounds were excluded from further
study. The numbers of CFU/ml were counted in 100-μl
aliquots of wound fluid. At days 4, 8, and 12 after wound-
ing, the overlaying fibrinous wound clot was carefully
removed and 4 punch tissue biopsies specimens were
taken per wound (one per quadrant). Each tissue sample
was subjected to surface decontamination by rinsing with
95% ethanol for 2 seconds, two times ignition for 5 sec-
onds, followed by three serial washes with sterile PBS[23].
Samples were then individually weighed and homoge-
nized in 1 ml of sterile 0.9% saline solution using a steri-
lized tissue homogenizer (Pro Scientific Inc, Oxford, CT
USA). Serial dilution was performed, and samples were
plated onto trypticase soy agar containing 5% sheep
blood agar (PML microbiologicals, Warwick, RI USA) for
total colony counts, mannitol salt agar (PML microbio-
logicals, Warwick, RI USA) for selective S. aureus detec-
tion, and Cetrimide selective medium (PML
microbiologicals, Warwick, RI USA) for P. aeruginosa. Fur-BMC Surgery 2008, 8:5 http://www.biomedcentral.com/1471-2482/8/5
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ther confirming tests included Gram-positive cocci:cata-
lase test and bacitracin disk test. All specimens were
incubated aerobically at 37°C for 24 hours. An additional
specimen obtained from the final wash solution for each
biopsy sample was also plated to detect potential surface
contamination. Findings on these plates precluded any
additional analysis of a biopsy sample[27]. All colony
counts were expressed as log10  colony-forming units
(CFU) per gram of tissue and ml wound fluid. Bacterial
counts >1 × 105 were considered to denote bacterial infec-
tion[28,29].
Statistic analysis
This study included a total of 56 wounds in 2 diabetic pigs
and 2 non-diabetic pigs divided into 4 experimental
groups:
A: Diabetic wounds treated with a sterile 0.9% saline solu-
tion (n = 14) B: Diabetic wounds inoculated 2 × 108 CFU
S. aureus (n = 14) C: Non-diabetic wounds treated with
sterile 0.9% saline solution (n = 14) D: Non-diabetic
wounds inoculated with 2 × 108 CFU S. aureus (n = 14).
Values are presented as means ± SE. Groups were com-
pared using the independent t-test, and statistical calcula-
tions were performed with GraphPad Instat software
(GraphPad Software, CA). A p-value < 0.05 was consid-
ered statistically significant.
Results
On day 1 post-wounding, all wounds showed clinical
signs of inflammation such as swelling and redness.
Wound inoculated with S. aureus became grossly purulent
by day 3. By day 4 the wound fluid was cloudy and a fibri-
nous-purulent wound clot formed on top of the wounds.
Control wounds exhibited a clear wound surface without
purulent debris and fibrin-clot formation on day 6. Meas-
urement of wound fluid glucose showed no detectable
concentration of glucose in non-diabetic animals. In dia-
betic animals non-inoculated wounds showed 350 mg/dl
glucose concentration on day 1 post injury, a decrease to
79 mg/dl on day 8, and glucose was undetectable on day
12; whereas S. aureus-inoculated wounds showed no
detectable glucose.
Localization of bacteria in the wound tissue
In non-diabetic wounds, hematoxylin-eosin staining
showed evenly formed new epithelium including connec-
tive tissue papillae (Fig. 1A). The Gram staining did not
show any gram-positive bacteria within the tissue (Fig.
1B).
In the diabetic wounds, the epithelium showed advanced
re-epithelialization by keratinocytes migrating from the
wound edges towards the centre of the defect by forming
epithelial tongues (Fig 1C). The Gram staining did not
show any bacteria within the wound tissue (Fig. 1D).
Diabetic wounds inoculated with S. aureus showed a less
organized newly formed epithelium compared with all
other groups (Fig 1E). In the tissue Gram staining, clusters
of Gram-positive cocci were detected within the granula-
tion tissue (Fig 1F), showing bacterial infection of the tis-
sue; whereas non-diabetic inoculated wounds showed no
detectable clusters in the tissue (Fig 1G and 1H).
Wound histology day 12, formalin-fixed and processed for  Hematoxylin/Eosin (HE) staining and Gram staining, respec- tively Figure 1
Wound histology day 12, formalin-fixed and proc-
essed for Hematoxylin/Eosin (HE) staining and Gram 
staining, respectively. A: Non-diabetic wound HE staining; 
B: Non-diabetic wound Gram staining; C: Diabetic wound HE 
staining; D: Diabetic wound Gram staining; E: Diabetic S. 
aureus-inoculated wound, HE staining; F: Diabetic S. aureus-
inoculated wound, Gram staining; G: Non-diabetic S. aureus-
inoculated wound, HE staining; H: Non-diabetic S. aureus-
inoculated wound, Gram staining.BMC Surgery 2008, 8:5 http://www.biomedcentral.com/1471-2482/8/5
Page 5 of 8
(page number not for citation purposes)
Quantification of bacteria in the wound tissue
Non-inoculated diabetic wounds showed the highest bac-
terial counts of the experiment on day 4 after wounding
with 1.8 × 107 CFU/g tissue. The infection decreased on
day 8 (1.2 × 106 CFU/g tissue) but still showed significant
invasive infection on the final day, with 2.2 × 105 CFU/g.
(Figure 2). Non-diabetic wounds showed significantly
lower counts on day 4 compared to diabetic wounds (3.4
× 103 CFU/g tissue; p =< 0.001). On day 8 3 × 105 CFU/g
tissue counts were detected (p =< 0.05 versus diabetic
wound tissue counts), and no apparent infection could be
detected on day 12 with 3.2 × 103 CFU/g tissue counts (p
=< 0.001 versus diabetic wounds; Table 1). Bacterial
counts >105 indicated significant invasive wound infec-
tion in diabetic wounds over the whole time course,
whereas non-diabetics showed significant infection only
on day 8 and no apparent bacterial burden on day 12 (Fig-
ure 2). Microorganisms were identified as E. coli, Strepto-
coccus dysgalactiae, and Enterococcus faecium. The selective
media for S. aureus and P. aeruginosa showed no colony
forming units in any wounds.
Quantification of bacteria in S. Aureus-inoculated 
wounds
Four days after wounding and inoculation with S. aureus,
diabetic wounds showed high bacterial counts in the
wound tissue (8.4 × 107  CFU/g tissue total bacterial
counts and 3.4 × 107 CFU/g tissue S. aureus counts). Dur-
ing the course of the study, inoculated diabetic wounds
revealed a sustained invasive infection, with tissue bacte-
rial counts consistently higher than 1 × 105 CFU/g tissue
with 4.4 × 106 CFU/g tissue total and 2.6 × 106 CFU/g tis-
sue S. aureus counts on day 8 and 1.2 × 106 CFU/g tissue
total, and 3.1 × 105 CFU/g tissue S. aureus counts on day
12 of the experiment, respectively (Figure 3).
Non-diabetic wounds showed similar results on day 4,
with 6.3 × 107 CFU/g tissue total and 4.4 × 107 CFU/g tis-
sue S. aureus counts followed by significantly lower counts
on day 8 (1.3 × 105 CFU/g tissue total counts; p < 0.01 and
5.5 × 104 CFU/g tissue S. aureus counts; p < 0.05) and no
apparent infection on day 12 of experiment, with 7.4 ×
102 CFU/g tissue total counts (p < 0.01) and no detectable
S. aureus counts (Figure 3, Table 2). The bacteria identified
were S. aureus, E. coli, Streptococcus dysgalactiae, and Entero-
coccus faecium.
Both, S. aureus inoculated wounds and control wounds
(not S. aureus inoculated) were on the same animals (in
all diabetic and non-diabetic pigs). There was no detecta-
ble S. aureus concentration in the control wounds, provid-
ing evidence that no cross-contamination occurred
between the wounds.
Re-epithelialization
In all groups, cross-sectional biopsies were taken on day
12 after surgery. Re-epithelialization in diabetic wounds
was significantly delayed compared to non-diabetic
wounds (84 +/- 15% versus 97 +/- 5%; p < 0.05).
Epidermal healing in diabetic wounds inoculated with S.
aureus showed a significant further delay compared with
non-inoculated wounds (59 +/- 8% versus 84 +/- 15%; p
< 0.05) and was highly significant compared with healing
in non-diabetic wounds (p < 0.001; Fig 4).
No significant difference in non-diabetic wounds inocu-
lated with S. aureus compared to non-inoculated wounds
(87 +/- 22% versus 97 +/- 5%) could be detected (Fig. 4).
Wound contraction
There was no statistical difference between diabetic (38 +/
- 11% wound contraction day 12) and non-diabetic
wounds (36 */- 12% wound contraction day 12).
S. aureus-inoculated diabetic wounds showed less contrac-
tion (24 +/- 23% wound contraction day 12) compared
with non-inoculated diabetic wounds (37 +/- 10% wound
contraction day 12); however, there was no significant dif-
ference between groups.
Discussion
Here we established a large-animal model for diabetic
infected wounds that allows the close monitoring of the
Bacterial counts in diabetic wounds and non-diabetic wounds  in colony-forming units/g tissue Figure 2
Bacterial counts in diabetic wounds and non-diabetic 
wounds in colony-forming units/g tissue. Day 4: 1.8 × 
107 versus 3.4 × 103 CFU/g tissue, p = X; Day 8 1.2 × 106 ver-
sus 3 × 105, p = X; Day 12 2.2 × 105 versus 3.2 × 103 CFU/g 
tissue, p = X). Microorganisms were identified as E. coli, 
Streptococcus dysgalactiae, and Enterococcus faecium. No S. 
aureus infection could be detected. # = p < 0.05 diabetic ver-
sus non-diabetic wounds; * = p < 0.001 diabetic versus non-
diabetic wounds.BMC Surgery 2008, 8:5 http://www.biomedcentral.com/1471-2482/8/5
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development of bacterial infections and controlled
manipulation of this complex environment.
Diabetic wounds showed significantly higher bacterial
counts compared with non-diabetic wounds. All identi-
fied bacteria (E. coli, Streptococcus dysgalactiae, and Entero-
coccus faecium) belong to the normal flora of the skin[30].
Thus, the data show that the natural skin flora itself
induced sustained bacterial infections in the wound tissue
in diabetic wounds, whereas non-diabetic organisms were
able to cope with endogenous bacterial contamination.
When inoculated with 2 × 108 CFU S. aureus, diabetic
wounds developed a high and sustained invasive infec-
tion over the whole time course of 12 days. Although non-
diabetic wounds showed high bacterial counts at day 4,
infection decreased to a lower bacterial count on day 8 fol-
lowed by no S. aureus counts and very few total bacteria
on the final day of the experiment. This result provides
additional support for the contention that non-diabetic
individuals are able to fight bacterial contamination
much more efficiently, whereas diabetics are more likely
to succumb to the bacterial challenge.
It is well known, though poorly understood, that diabetes
mellitus impairs wound healing. High glucose concentra-
tions in the wound fluid of diabetic wounds might be a
major reason for increased bacterial growth[31,32]. Here
we closely followed the blood glucose concentration of
the wound fluid within the first week and detected high
glucose concentrations. The presence of bacteria in the
wound immediately lowered the high wound fluid glu-
cose concentration, indicating that bacteria utilize the glu-
cose present in diabetic wounds. Dysfunction of
polymorphonuclear neutrophils and macrophages and
reduced chemotaxis of leukocytes seems to be another key
to enhanced susceptibility to infections[6,31-33]. Per-
schel et al describe neuropathy, vascular damage, dehy-
dration, electrolyte disturbance and malnutrition as
further reasons for higher susceptibility to wound infec-
tions[34]. In our model, a diabetic metabolic state was
induced only two weeks prior to the experiment, which
suggests that no long-term side effects such as neuropathy
are responsible for increased bacterial infection and
impaired wound healing. This also highlights a limitation
of our model; since it omits long-term effects such as neu-
A: Total bacterial counts in S. aureus-inoculated diabetic and  non-diabetic wounds in colony-forming units/g tissue Figure 3
A: Total bacterial counts in S. aureus-inoculated dia-
betic and non-diabetic wounds in colony-forming 
units/g tissue. # = p < 0.001 diabetic versus non-diabetic 
wounds; B: Selective S. aureus counts in S. aureus-inoculated 
diabetic and non-diabetic wounds in colony-forming units/g 
tissue.
Re-epithelialization on day 12 of experiment Figure 4
Re-epithelialization on day 12 of experiment. Non-dia-
betic wounds 97*/- 5% reepithelialization, S. aureus-inocu-
lated non-diabetic wounds: 87+/- 22%. Diabetic wounds 
showed 84 +/- 15%, and S. aureus-inoculated diabetic wounds 
were 59 +/- 8% reepithelialized. + = p < 0.05 diabetic versus 
non-diabetic wounds; * = p < 0.05 S. aureus-noculated dia-
betic versus non-inoculated diabetic wounds; # = p < 0.05 S. 
aureus-inoculated diabetic versus S. aureus-inoculated non-
diabetic wounds; § = p < 0.001 S. aureus-inoculated diabetic 
wounds versus non-diabetic wounds.BMC Surgery 2008, 8:5 http://www.biomedcentral.com/1471-2482/8/5
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ropathy, vasculopathy, and foot deformity[35]. Staphylo-
coccus aureus inoculation of the diabetic wounds led to a
higher rate of infection and increased co-infection with
endogenous bacterial strains, which further underlines
the enhanced susceptibility of diabetic wounds to bacte-
rial infections. No cross-contamination between inocu-
lated and non-inoculated wounds could be detected,
indicating that this model can be used for reliable com-
parative infectious studies.
Bacterial concentrations were consistently higher in the
wound fluid than in the wound tissue, and strains found
in the fluid sometimes differed from the strains found in
the tissue (data not shown). This finding confirms the
results described by Breuing and coworkers in porcine
burn wounds, indicating that the assessment and quanti-
fication of superficial wound infection does not reflect the
situation in the wound tissue[23]. These data support the
hypothesis that obtaining superficial wound swabs for
diagnosis and determination of infection is insufficient
and should be replaced by tissue biopsies if possi-
ble[4,23].
Diabetic wounds showed a significantly delayed reepithe-
lialization compared to non-diabetic wounds. Inocula-
tion with S. aureus caused a further delay in diabetic
wound healing. In non-diabetic animals, bacterial inocu-
lation caused only a non-significant delay in wound heal-
ing, confirming the previous finding that diabetic animals
have higher susceptibility and experience more severe
complications after bacterial challenge.
Steinstraesser et al previously described an implantable
titanium chamber in non-diabetic pigs[24]. The impaired
wound healing induced by the implanted chamber creates
a good environment for bacterial growth. However, it also
prevents reepithelialization from the wound edges and
thus is not suitable for wound healing analysis or contrac-
tion measurements. Wound healing assessment presents
an important tool to obtain a comprehensive picture of
the progress of infected wounds and potential effects of
therapeutical agents. Particularly in diabetic wounds, we
consider final wound closure one of the cornerstones of
infection studies.
Conclusion
This novel animal model shows characteristics of a dia-
betic infected wound and demonstrates enhanced co-
infection of diabetic wounds when inoculated with S.
aureus. Diabetic infected wounds have significantly
delayed healing, whereas non-diabetic wounds show no
invasive infection by the bacteria of the skin flora, and
even bacterial inoculation did not induce a sustained
invasive infection. This study shows that diabetic wounds
are significantly more susceptible to wound infections by
endogenous bacterial challenge as well as external con-
tamination than non-diabetic wounds. The wound cham-
bers provide a reliable and feasible system in which to
apply defined numbers of bacteria to diabetic wounds,
inducing deep tissue infection and allowing the study of
diabetic wound infections and therapeutic approaches
preclinically in a large-animal model. Moreover, the
opportunity to create as many as 14 wounds in one pig
reduces interindividual variability, improves statistical
power, and provides a reliable and reproducible in vivo
model to investigate wound healing, wound infection,
and treatment options. This model may be useful for
future studies such as efficacy studies for commonly used
antibiotics, new therapeutic approaches, or studies con-
cerning cell migration and molecular mechanisms in vivo.
Thus, results from the use of this animal model may be
beneficial for clinical approaches and new therapeutic
strategies.
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